Generic Name

LamoTRIgine

Brand Names
Subvenite, Lamictal, Lamictal ODT
FDA approval date: January 17, 1995
Classification: Anti-epileptic Agent
Form: Tablet, Kit, Suspension

What is Subvenite (LamoTRIgine)?

Living with epilepsy or bipolar disorder can be unpredictable, one day may feel calm, and the next, symptoms can interfere with daily life. Lamotrigine is a medication that helps bring stability, offering control over seizures and mood swings so patients can regain a sense of balance and confidence.

Lamotrigine belongs to a class of drugs called anticonvulsants (or antiepileptic drugs). It’s used both for seizure management and as a mood stabilizer in bipolar disorder. Approved by the U.S. Food and Drug Administration (FDA) in the 1990s, Lamotrigine has become a well-established therapy for long-term use. Many patients find it effective with relatively few side effects compared to some older medications.

What does Lamotrigine do?

Lamotrigine is primarily prescribed to treat epilepsy and bipolar I disorder. For people with epilepsy, it helps reduce the frequency and intensity of seizures, which can dramatically improve safety, independence, and overall quality of life.

In bipolar disorder, Lamotrigine works differently from many other treatments. Instead of primarily targeting manic episodes like lithium or valproate, Lamotrigine helps prevent depressive episodes, often the more challenging and longer-lasting aspect of the condition.

Clinical research shows that Lamotrigine can significantly decrease the recurrence of mood episodes in bipolar disorder and effectively manage seizures when used consistently and monitored appropriately (Mayo Clinic, 2023; FDA, 2023).

Because of its dual benefits, Lamotrigine is sometimes considered a first-line option, especially for patients needing both seizure control and mood stabilization.

How does Lamotrigine work?

Lamotrigine works by calming overactive electrical activity in the brain. It blocks specific sodium channels on nerve cells, which prevents excessive electrical impulses from spreading. By stabilizing these signals, the drug helps control seizures and reduces the sudden mood fluctuations seen in bipolar disorder.

Additionally, Lamotrigine influences the release of certain neurotransmitters, brain chemicals involved in mood regulation, particularly glutamate and aspartate, which play key roles in both seizure activity and emotional balance.

From a clinical standpoint, this dual action is important because it allows Lamotrigine to target both neurological and psychiatric symptoms without the sedation or weight gain commonly seen with some other medications.

Lamotrigine side effects

Like all medications, Lamotrigine can cause side effects, but many are mild and temporary. Still, it’s important to be aware of possible reactions so they can be managed early.

Common side effects include:

  • Headache or dizziness
  • Drowsiness or fatigue
  • Blurred or double vision
  • Nausea or vomiting
  • Mild skin rash

Less common but serious side effects:

  • Severe skin reactions, including Stevens-Johnson syndrome (SJS)
  • Fever or flu-like symptoms before a rash develops
  • Swelling of lymph nodes
  • Signs of liver problems such as dark urine or yellowing of the skin

The most important precaution with Lamotrigine is the risk of serious rash, which can occur if the medication is increased too quickly. This is why doctors start patients on a low dose and gradually raise it to safe levels.

Who should avoid Lamotrigine? People with a history of allergic reactions to anticonvulsants, liver problems, or those who developed rash or hypersensitivity from Lamotrigine in the past should not take it again.

When to seek urgent medical help: If you develop a rash, fever, swollen glands or any unexplained flu-like symptoms, contact your healthcare provider immediately. Early intervention can prevent complications.

Lamotrigine dosage

Lamotrigine is available in multiple forms, including tablets, chewable dispersible tablets, and orally disintegrating tablets. It is taken once or twice daily depending on the treatment plan.

Doctors typically start with a low dose and gradually increase it over several weeks to minimize the risk of side effects, particularly skin reactions. Because individual responses can vary, the dosing schedule is personalized for each patient.

Your healthcare provider may monitor your skin health, liver function, and mental well-being, especially during the early stages of treatment or when adjusting the dose.

For patients with kidney or liver disease, dose adjustments may be necessary. Older adults may also require closer observation for dizziness or balance issues.

Patients taking valproate (Depakote) or carbamazepine (Tegretol) may need specific Lamotrigine dosing adjustments, as these drugs can interact and alter its levels in the body.

Does Lamotrigine have a generic version?

Yes. Lamotrigine is available in a generic form, which is FDA-approved and considered equally safe and effective as the brand-name version, Lamictal. The generic versions undergo the same quality and safety checks to ensure consistent performance.

Both generic Lamotrigine and Lamictal are available in a variety of tablet strengths and formulations, making it easier for doctors to tailor treatment to individual patient needs.

Choosing the generic form can significantly reduce medication costs without compromising treatment quality, an important consideration for patients on long-term therapy.

Conclusion

Lamotrigine is a reliable and well-studied medication that helps many patients gain control over seizures and mood instability. By stabilizing brain activity and regulating neurotransmitter function, it offers lasting relief and helps patients live more balanced, independent lives.

While generally well-tolerated, Lamotrigine must be introduced gradually and monitored closely to minimize the risk of rash and other side effects. Patients should never adjust doses or stop the medication suddenly without medical advice.

When prescribed and monitored by a qualified healthcare provider, Lamotrigine can be a cornerstone of effective treatment for epilepsy and bipolar disorder, helping patients reclaim stability, confidence, and a better quality of life.

References

  1. U.S. Food and Drug Administration (FDA). (2023). Lamotrigine Medication Guide. https://www.fda.gov/
  2. Mayo Clinic. (2023). Lamotrigine (Oral Route): Uses and Precautions. https://www.mayoclinic.org/
  3. MedlinePlus. (2023). Lamotrigine: Drug Information. https://medlineplus.gov/
  4. National Institute of Mental Health (NIMH). (2023). Bipolar Disorder Treatment Options. https://www.nih.gov/

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

There is no latest advances for this treatment

Brand Information

    SUBVENITE (LAMOTRIGINE)
    1DESCRIPTION
    SUBVENITE (lamotrigine) oral suspension, an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine’s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-
    structure
    SUBVENITE oral ouspension  contains 10 mg per mL lamotrigine, USP and the following inactive ingredients: carboxymethylcellulose sodium, cherry flavor, FD&C Red 40, FD&C Yellow 6,glycerin, methylparaben, polyethylene glycol, propylene glycol, purified water, saccharin sodium, silicified microcrystalline cellulose, sodium benzoate, sodium phosphate dibasic, sorbitol solution, sucralose and xanthan gum.
    2PATIENT COUNSELING INFORMATION
    Advise the patient to read the FDA-approved patient labeling (Medication Guide). 
    Rash
    Prior to initiation of treatment with SUBVENITE, inform patients that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and instruct them to report any such occurrence to their healthcare providers immediately
    Administration
    Instruct patients or caregivers that a calibrated measuring device, such as an oral dosing syringe or oral dosing cup, should be obtained from the pharmacy to accurately measure and deliver the prescribed dose of medication. A household teaspoon or tablespoon is not an adequate measuring device.
    Instruct patients to shake well before each use and to discard any unused portion 90 days after first opening the bottle.
    Hemophagocytic Lymphohistiocytosis
    Prior to initiation of treatment with SUBVENITE, inform patients that excessive immune activation may occur with SUBVENITE and that they should report signs or symptoms such as fever, rash, or lymphadenopathy to a healthcare provider immediately
    DRESS/Multiorgan Hypersensitivity Reactions, Blood Dyscrasias, and Organ Failure
    Instruct patients and caregivers that a fever or rash associated with signs of other organ system involvement (e.g., lymphadenopathy, hepatic dysfunction) may be drug-related. SUBVENITE should be discontinued immediately if a serious hypersensitivity reaction is suspected Isolated organ failure or isolated blood dyscrasias without evidence of multiorgan hypersensitivity may also occur. Instruct patients to contact their healthcare providers immediately if they experience any signs or symptoms of these conditions
    Cardiac Rhythm and Conduction Abnormalities
    Inform patients that, due to its mechanism of action, SUBVENITE could lead to irregular or slowed heart rhythm. This risk is increased in patients with underlying cardiac disease or heart conduction problems or who are taking other medications that affect heart conduction. Patients should be made aware of and report cardiac signs or symptoms to their healthcare provider right away. Patients who develop syncope should lie down with raised legs and contact their healthcare provider
    Suicidal Thinking and Behavior
    Inform patients, their caregivers, and families that AEDs, including SUBVENITE, may increase the risk of suicidal thoughts and behavior. Instruct them to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior or thoughts about self-harm. Instruct them to immediately report behaviors of concern to their healthcare providers
    Worsening of Seizures
    Instruct patients to notify their healthcare providers if worsening of seizure control occurs
    Central Nervous System Adverse Reactions
    Inform patients that SUBVENITE may cause dizziness, somnolence, and other symptoms and signs of central nervous system depression. Accordingly, instruct them neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on SUBVENITE to gauge whether or not it adversely affects their mental and/or motor performance.
    Pregnancy and Lactation
    Instruct patients to notify their healthcare providers if they become pregnant or intend to become pregnant during therapy and if they intend to breastfeed or are breastfeeding an infant.
    Encourage patients to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of AEDs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 [see Use in Specific Populations (8.1)].
    Inform patients who intend to breastfeed that SUBVENITE is present in breast milk and advise them to monitor their child for potential adverse effects of this drug. Discuss the benefits and risks of continuing breastfeeding.
    Use of Estrogen-Containing Products, Including Oral Contraceptives
    Instruct women to notify their healthcare providers if they plan to start or stop use of oral contraceptives or other female hormonal preparations (including HRT). Starting estrogen-containing products, including oral contraceptives, may significantly decrease lamotrigine plasma levels and stopping estrogen-containing oral contraceptives (including the pill-free week) may significantly increase lamotrigine plasma levels
    Discontinuing SUBVENITE
    Instruct patients to contact their healthcare providers before stopping SUBVENITE for any reason and to consult with their healthcare providers before resuming SUBVENITE
    Inform patients that SUBVENITE may cause aseptic meningitis. Instruct them to notify their healthcare providers immediately if they develop signs and symptoms of meningitis such as headache, fever, nausea, vomiting, stiff neck, rash, abnormal sensitivity to light, myalgia, chills, confusion, or drowsiness while taking SUBVENITE.  
    Potential Medication Errors
    To avoid a medication error of using the wrong drug or formulation, strongly advise patients to visually inspect their product to verify that it is SUBVENITE, as well as the correct formulation of lamotrigine, each time they fill their prescription
    3PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 10 mg/mL
    240 mL Suspension
    NDC 69102-418-01
    SUBVENITE
    (lamotrigine) Oral Suspension, 10 mg/mL
    Rx Only
    Container Label
    Carton Label
    carton